Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women’s health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.